Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 4Mucositis 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Febrile Neutropenia 2Cytokine Release Syndrome 2Burkitt Lymphoma 2Smoldering Multiple Myeloma 1Recurrence 1Rectal Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Neurotoxicity Syndromes 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1Early Stage Triple Negative ER Low Breast Cancer 1Disease Progression 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 72fludarabine 65Tacrolimus 43fludarabine phosphate 40Whole-Body Irradiation 37Mycophenolic Acid 35Busulfan 32Melphalan 28Antilymphocyte Serum 23thymoglobulin 22Thiotepa 20Methotrexate 20Standard of Care 19Stem Cell Transplantation 17Practice Guidelines as Topic 17Granulocyte Colony-Stimulating Factor 17Rituximab 15Surveys and Questionnaires 12Sirolimus 12Filgrastim 12Interviews as Topic 11Cyclosporine 11Blood Specimen Collection 11Peripheral Blood Stem Cell Transplantation 10Exercise 10venetoclax 9Mesna 9Cytarabine 9Bortezomib 9Hematopoietic Stem Cell Transplantation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hematologic Neoplasms × Interleukin 1 Receptor Antagonist Protein × Clear all
NCT04432506 2025-01-28

Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
22 enrolled 15 charts
LymphoidOther hematologic neoplasm

Lymphoma, Large B-Cell, Diffuse, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡